<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02183038</url>
  </required_header>
  <id_info>
    <org_study_id>107.193</org_study_id>
    <nct_id>NCT02183038</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis</brief_title>
  <official_title>Double-blind Study to Compare Efficacy and Safety of Meloxicam 7.5 mg and 15 mg vs. Naproxen Sodium 1100 mg in the Symptomatic Treatment of Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis Over a Period of 5 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess the efficacy and tolerability of Meloxicam once daily dose of 7.5 mg and 15&#xD;
      mg compared with 1100 mg of naproxen sodium in the symptomatic treatment of acute non&#xD;
      bacterial pharyngitis or pharyngo-tonsillitis, over a period of 5 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1998</start_date>
  <primary_completion_date type="Actual">February 1999</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in intensity of spontaneous pharyngeal pain</measure>
    <time_frame>Baseline, day 3 and 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in intensity of pharyngeal pain on swallowing</measure>
    <time_frame>Baseline, day 3 and 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of efficacy by patient</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of efficacy by investigator</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of tolerability by patient</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of tolerability by investigator</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of disease systemic manifestations (fever, and general malaise)</measure>
    <time_frame>up to 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of pharyngeal hyperemia</measure>
    <time_frame>up to 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of patient status</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of treatment withdrawal due to lack of efficacy</measure>
    <time_frame>up to 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of perforation, ulceration, bleeding (PUB) of the upper gastro-intestinal tract (stomach or duodenum)</measure>
    <time_frame>up to day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of adverse events</measure>
    <time_frame>up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who withdraw due to adverse event</measure>
    <time_frame>up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of significant laboratory adverse events</measure>
    <time_frame>up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and duration of hospital stay due to Gastro-Intestinal Serious Adverse Events (GI-SAE)</measure>
    <time_frame>up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and duration of hospital stay due to adverse events related to trial drug administration</measure>
    <time_frame>up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of an additional visit at physician due to gastro-intestinal adverse event (GI-AE)</measure>
    <time_frame>up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events related to trial drug</measure>
    <time_frame>up to 19 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">390</enrollment>
  <condition>Pharyngitis</condition>
  <arm_group>
    <arm_group_label>Meloxicam low &amp; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Meloxicam high &amp; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen sodium &amp; Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam low</intervention_name>
    <arm_group_label>Meloxicam low &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam high</intervention_name>
    <arm_group_label>Meloxicam high &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen sodium</intervention_name>
    <arm_group_label>Naproxen sodium &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam placebo low</intervention_name>
    <arm_group_label>Meloxicam high &amp; Placebo</arm_group_label>
    <arm_group_label>Naproxen sodium &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam placebo high</intervention_name>
    <arm_group_label>Meloxicam low &amp; Placebo</arm_group_label>
    <arm_group_label>Naproxen sodium &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen sodium placebo</intervention_name>
    <arm_group_label>Meloxicam high &amp; Placebo</arm_group_label>
    <arm_group_label>Meloxicam low &amp; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 18 years or above&#xD;
&#xD;
          -  Ambulatory patients&#xD;
&#xD;
          -  Start of symptoms within the previous 24 hours&#xD;
&#xD;
          -  Patients suffering from acute non bacterial pharyngitis or pharyngo-tonsillitis&#xD;
             diagnostic, under the following criteria:&#xD;
&#xD;
               -  spontaneous pharyngeal pain presence greater than 35 mm on a 100 mm visual analog&#xD;
                  scale (VAS)&#xD;
&#xD;
               -  Pharyngeal pain presence on swallowing greater than 35 mm on a 100 mm VAS&#xD;
&#xD;
               -  Pharyngeal and/or amygdaline hyperemia&#xD;
&#xD;
               -  Absence of purulent plaques&#xD;
&#xD;
               -  Negative test for β-haemolytic Streptococcus on pharyngeal exudate&#xD;
&#xD;
          -  Therapy with NSAID (Non-Steroid Anti-Inflammatory Drug) is required or recommended&#xD;
&#xD;
          -  Patient's informed consent in accordance with local law and ICH GCP (International&#xD;
             Conference of Harmonization Good Clinical Practice) , before inclusion into the the&#xD;
             trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suspicion of acute pharyngitis or pharyngo-tonsillitis from bacterial origin by&#xD;
             clinical criteria; Several impairment of patients condition, indicated by one or more&#xD;
             or the following symptoms:&#xD;
&#xD;
               -  Extremely rapid onset of clinical picture&#xD;
&#xD;
               -  Very high fever (&gt;38.5°C)&#xD;
&#xD;
               -  Severe pharyngeal pain&#xD;
&#xD;
               -  Cervical adenopathy&#xD;
&#xD;
               -  Intense headache&#xD;
&#xD;
               -  Purulent pharyngeal plaques, evidence of peritonsillar abscess or phlegmon&#xD;
&#xD;
          -  Known or suspected hypersensitivity to the trial drug or NSAIDs&#xD;
&#xD;
          -  Positive test for β-haemolytic Streptococcus on pharyngeal exudate&#xD;
&#xD;
          -  Therapy with antimicrobial agents prior to start of the trial&#xD;
&#xD;
          -  Chronic infections&#xD;
&#xD;
          -  Infectious mononucleosis&#xD;
&#xD;
          -  Active peptic ulcer within the past 6 months&#xD;
&#xD;
          -  Pregnancy or breast feeding precaution: attention should be drawn to reports that&#xD;
             NSAIDs were reported to decrease the efficacy of intrauterine devices&#xD;
&#xD;
          -  Asthma, nasal polyps, angioneurotic edema or urticaria following the administration of&#xD;
             aspirin or NSAIDs&#xD;
&#xD;
          -  Concomitant treatment with anti-coagulants (including heparin), lithium or&#xD;
             methotrexate&#xD;
&#xD;
          -  Concomitant administration of other NSAIDs (including high-dose &gt; 1500 mg at day&#xD;
             aspirin) or analgesic agents&#xD;
&#xD;
          -  Administration of any NSAID during the last three days or analgesics 6 hours prior to&#xD;
             the first administration of the trial drug&#xD;
&#xD;
          -  Present treatment or treatment within the last two months with corticosteroids&#xD;
&#xD;
          -  Historically know of impaired renal function (serum urea &gt; 125 % of the upper limit of&#xD;
             normal range; serum creatinine &gt; 150 % of the upper limit of normal range)&#xD;
&#xD;
          -  Historically know of severe liver injury (alanine amino transferase ALAT &gt; 2 x the&#xD;
             upper normal range limit or aspartate amino transferase ASAT &gt; 2 x the upper normal&#xD;
             range limit)&#xD;
&#xD;
          -  Historically know of hematological disorder (platelet count &lt; 100,000/mm3, leucocyte&#xD;
             count &lt; 3,000/mm3)&#xD;
&#xD;
          -  Participation in another clinical trial during this study or during the previous month&#xD;
&#xD;
          -  Previous participation in this trial&#xD;
&#xD;
          -  Patient unable to comply with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/107/107.193_U01-3344.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharyngitis</mesh_term>
    <mesh_term>Tonsillitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

